Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Laurus Labs Ltd.

Latest From Laurus Labs Ltd.

Krka To Plant Its Flag In India With Laurus Labs JV

Delivering record annual sales and profits according to preliminary financial results, Slovenia’s Krka will soon look to set up shop in India via a new company established with local big player Laurus Labs.

Deals Strategy

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

Research & Development Innovation

India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices

ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.

India Approvals

Shionogi's Xocova Extends Global Reach Through First MPP Sublicenses

The first sublicensing deals through MPP for Shionogi's oral COVID antiviral Xocova with seven firms in China, India, Ukraine and Vietnam suggest the global debut of generic versions will come earlier than usual after the original, which continues in multiple global Phase III programs in various settings. While sales hopes are high, the drug may also be hit by a price cut in its first and biggest market so far – Japan.


Commercial Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs